EAM
NKTR icon

Erste Asset Management’s Nektar Therapeutics NKTR Stock Holding History

Erste Asset Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.83M Hold
28,000
– – 0.01% 393
2026
Q1 		$1.83M Hold
28,000
– – 0.02% 375
2025
Q4 		$1.2M Buy
28,000
+11,000
+65% +$616K 0.01% 420
2025
Q3 		$1M Buy
+17,000
New +$563K 0.01% 413
2024
Q4 		– Sell
-3,120
Closed -$54.8K – 561
2024
Q3 		$54.8K Hold
3,120
– – ﹤0.01% 510
2024
Q2 		$53.4K Hold
3,120
– – ﹤0.01% 508
2024
Q1 		$41.4K Hold
3,120
– – ﹤0.01% 507
2023
Q4 		$25.8K Hold
3,120
– – ﹤0.01% 527
2023
Q3 		$28.5K Hold
3,120
– – ﹤0.01% 526
2023
Q2 		$27K Hold
3,120
– – ﹤0.01% 553
2023
Q1 		$29.8K Hold
3,120
– – ﹤0.01% 566
2022
Q4 		$103K Hold
3,120
– – ﹤0.01% 531
2022
Q3 		$142K Hold
3,120
– – ﹤0.01% 512
2022
Q2 		$185K Hold
3,120
– – ﹤0.01% 514
2022
Q1 		$261K Hold
3,120
– – 0.01% 493
2021
Q4 		$665K Hold
3,120
– – 0.01% 401
2021
Q3 		$839K Hold
3,120
– – 0.02% 352
2021
Q2 		$815K Hold
3,120
– – 0.02% 363
2021
Q1 		$913K Hold
3,120
– – 0.02% 337
2020
Q4 		$854K Sell
3,120
-733
-19% -$189K 0.02% 349
2020
Q3 		$976K Hold
3,853
– – 0.03% 303
2020
Q2 		$1.3M Hold
3,853
– – 0.05% 274
2020
Q1 		$1.04M Buy
3,853
+1,000
+35% +$309K 0.06% 249
2019
Q4 		$923K Sell
2,853
-314
-10% -$91.1K 0.04% 284
2019
Q3 		$850K Sell
3,167
-5,866
-65% -$2.15M 0.05% 277
2019
Q2 		$4.7M Buy
9,033
+1,313
+17% +$658K 0.25% 107
2019
Q1 		$3.79M Hold
7,720
– – 0.21% 116
2018
Q4 		$3.84M Buy
+7,720
New +$4.66M 0.26% 104

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Erste Asset Management's NKTR Position: Q2 2026 in Review

Erste Asset Management held its Nektar Therapeutics (NKTR) position steady in Q2 2026 at 28,000 shares worth $1.83M. The position accounts for 0.01% of the portfolio, ranked #393.

Erste Asset Management first reported a position in NKTR in Q4 2018 and has held it in 28 quarters since. The position peaked at $4.7M in Q2 2019. 239 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • Erste Asset Management held 28,000 shares of Nektar Therapeutics worth $1.83M as of Q2 2026.
  • Erste Asset Management left its Nektar Therapeutics share count unchanged in Q2 2026.
  • Nektar Therapeutics made up 0.01% of Erste Asset Management's portfolio in Q2 2026, its #393 holding.
  • Erste Asset Management first reported a position in Nektar Therapeutics in Q4 2018 and has held it in 28 quarters since.
  • Erste Asset Management's Nektar Therapeutics position peaked at $4.7M in Q2 2019.
  • 239 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Erste Asset Management's 13F filing for Q2 2026, filed 28 Jul 2026.